ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
First Abu Dhabi Bank Reports 22% Jump in Q4 Profit, Beats Market Expectations 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges 
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI 
BYD and Exxon Mobil Strengthen Hybrid Technology Partnership 
The Maire - EuroChem Case: Three Lessons for Global Business 
China Approves First Import Batch of Nvidia H200 AI Chips Amid Strategic Shift 
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
California Governor Gavin Newsom Launches Review Into Alleged TikTok Content Suppression After U.S. Ownership Deal 
Citigroup Faces Lawsuit Over Alleged Sexual Harassment by Top Wealth Executive 
UK Politicians Call for Full Competition Review of Netflix’s Warner Bros Discovery Deal 
Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage 
NEW YORK, May 17, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired shares of Neurotrope, Inc. (“Neurotrope”) (NASDAQ:NTRP) between January 7, 2016, and April 28, 2017. You are hereby notified that Levi & Korsinsky has commenced the action Hinshaw v. Neurotrope, Inc., et al. (Case No. 1:17-cv-03718) in the USDC for the Southern District of New York. To get more information go to:
http://www.zlk.com/pslra/neurotrope-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that, throughout the class period, Neurotrope issued materially false and misleading statements and/or failed to disclose material information concerning the efficacy of its lead product candidate, Bryostatin-1. On May 1, 2017, Neurotrope issued a press release announcing “positive top-line results” of the pivotal Phase 2b trials of Bryostatin-1, noting “improvement in patients with moderate to severe Alzheimer’s disease.” However, the underlying trial data contradicts these representations, as the top-line data relating to the 20 microgram dose of Bryostatin-1 failed to produce results that were statistically significant. In addition, Neurotrope failed to disclose statements regarding the efficacy of the 40 microgram dose with regard to its primary and secondary endpoints. Upon this news, shares of Neurotrope fell from a close of $18.81 on April 28, 2017, to a close of $6.97 per share on May 1, 2017.
Take Action: if you suffered a loss in Neurotrope you have until July 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
